Applied Genetic Technologies Corp (NASDAQ: AGTC) today conveyed 12-month statistics from its ongoing achromatopsia (ACHM) Phase 1/2 scientific trials, including statistics from all adult patients and low-dose pediatric patients.
Consequences reveal biological movement based on enhancements in visual sensitivity
For its ACHM B3 applicant, results validate biologic activity based on enhancements in visual sensitivity in the treated part measured by static perimetry and light uneasiness measured by the Ocular Photosensitivity Analyzer (OPA). In addition, the security outline of the company’s ophthalmic gene therapy stage remained promising. Founded on these statistics, AGTC intends to progress the ACHM B3 pilot to the next phase of scientific development. The path onward for ACHM A3 will be governed after additional pediatric patient data and preclinical studies are obtainable and can be assessed.
“The consequences regarding responders in the ACHM B3 trial are heartening,” said Rachel Huckfeldt, MD, Ph.D., Assistant Professor of Ophthalmology at Harvard Medical School and an investigator on the ongoing AGTC achromatopsia Phase 1/2 trials. “The statistics from the ACHM B3 pilot support further scientific study of this applicant, and data from added pediatric patients may support the concentrated development of the ACHM A3 candidate precisely in younger patients.”
“We are extremely satisfied with these statistics, which further support AGTC as a front-runner in the arena of ophthalmic gene treatment. Our strong competences lead to discerned products founded on strong manufacturing, and demanding preclinical assessment of our product applicants in authenticated models of retinal illnesses,” said Sue Washer, President and CEO of AGTC.
ACHM B3 12-Month Consequences
12-month statistics, obtained for 25 patients, comprising 21 adult and four pediatric patients, show sustained enhancements on perimetry for higher dosage and younger patients and embrace positive patient narratives. Perceived improvements in retinal sensitivity as measured by still perimetry was observed in the treated eye compared with the untreated eye in four of 11 patients from the high-dose and pediatric cohorts.